CR20130287A - Tableta oralmente desintegradora - Google Patents

Tableta oralmente desintegradora

Info

Publication number
CR20130287A
CR20130287A CR20130287A CR20130287A CR20130287A CR 20130287 A CR20130287 A CR 20130287A CR 20130287 A CR20130287 A CR 20130287A CR 20130287 A CR20130287 A CR 20130287A CR 20130287 A CR20130287 A CR 20130287A
Authority
CR
Costa Rica
Prior art keywords
tablet
detaching
orally
active ingredients
proton pump
Prior art date
Application number
CR20130287A
Other languages
English (en)
Inventor
Yasushi Mima
Tetsuya Kawano
Yumiko Ishii
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20130287A publication Critical patent/CR20130287A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CR20130287A 2010-12-03 2013-06-13 Tableta oralmente desintegradora CR20130287A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010270276 2010-12-03

Publications (1)

Publication Number Publication Date
CR20130287A true CR20130287A (es) 2013-10-07

Family

ID=46172031

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130287A CR20130287A (es) 2010-12-03 2013-06-13 Tableta oralmente desintegradora

Country Status (22)

Country Link
US (1) US20130243859A1 (es)
EP (1) EP2647381A4 (es)
JP (1) JP6037840B2 (es)
KR (1) KR101908748B1 (es)
CN (1) CN103338774A (es)
AU (1) AU2011337549A1 (es)
BR (1) BR112013013571A2 (es)
CA (1) CA2819460C (es)
CL (1) CL2013001566A1 (es)
CO (1) CO6721054A2 (es)
CR (1) CR20130287A (es)
DO (1) DOP2013000122A (es)
EA (1) EA201390814A1 (es)
EC (1) ECSP13012717A (es)
MX (1) MX2013006247A (es)
MY (1) MY180677A (es)
PE (1) PE20140005A1 (es)
PH (1) PH12013501119B1 (es)
SG (1) SG190717A1 (es)
TN (1) TN2013000229A1 (es)
WO (1) WO2012074110A1 (es)
ZA (1) ZA201304366B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402400YA (en) * 2011-11-30 2014-06-27 Takeda Pharmaceutical Dry coated tablet
US9693962B2 (en) 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
EP3000470A4 (en) * 2013-05-21 2017-01-11 Takeda Pharmaceutical Company Limited Orally disintegrable tablet
JP2015020964A (ja) * 2013-07-17 2015-02-02 日本曹達株式会社 ヒドロキシプロピルセルロース
BR112017009521A2 (pt) 2014-11-11 2017-12-19 Shionogi & Co comprimido de múltiplas camadas que contém um fármaco instável à luz
SI3236952T1 (sl) * 2014-12-23 2019-11-29 Krka D D Novo Mesto Farmacevtski sestavek v obliki tablet
BR112017019918B1 (pt) * 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para produzir uma preparação sólida farmacêutica para estabilizar uma preparação sólida farmacêutica
CN107427483B (zh) 2015-03-19 2021-06-29 第一三共株式会社 含有着色剂的固体制剂
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7050484B2 (ja) * 2017-12-26 2022-04-08 ライオン株式会社 積層錠、医薬製剤及び積層錠の製造方法
ES2943883T3 (es) 2018-07-30 2023-06-16 Daiichi Sankyo Co Ltd Formulación de fármaco sólido que contiene estabilizador
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN115040491A (zh) * 2021-03-09 2022-09-13 上海天慈生物谷生物工程有限公司 钾离子竞争性酸阻滞剂和乙酰水杨酸的复方制剂及其制备方法
CN113230221B (zh) * 2021-04-06 2022-11-04 北京诚济制药股份有限公司 一种铝镁匹林片(ⅱ)
KR20230149188A (ko) 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
EP4512405A4 (en) 2022-04-19 2026-04-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising acetylsalicylic acid and a proton pump inhibitor
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
WO1995010264A1 (en) * 1993-10-12 1995-04-20 Tokyo Tanabe Company Limited Tablet containing enteric granules
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
KR100775802B1 (ko) 2000-04-28 2007-11-12 다케다 야쿠힌 고교 가부시키가이샤 광학 활성 술폭시드 유도체의 제조 방법
CN100562318C (zh) 2000-05-15 2009-11-25 武田药品工业株式会社 晶体的制备方法
JP2002029964A (ja) * 2000-07-11 2002-01-29 Lion Corp 固形医薬組成物
JP2002154966A (ja) * 2000-11-22 2002-05-28 Taisho Pharmaceut Co Ltd アセチルサリチル酸アルミニウム含有組成物
ATE511508T1 (de) 2000-12-01 2011-06-15 Takeda Pharmaceutical Verfahren zur kristallisation von (r)- oder (s)- lansoprazol
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
BR0211117A (pt) * 2001-07-16 2004-06-22 Astrazeneca Ab Tablete multiparticulado, processo para a manufatura e uso do mesmo, e, método e tratamento de distúrbios gastrointestinais
US6930099B2 (en) * 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
MXPA06013585A (es) * 2004-05-25 2009-07-22 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas.
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
BRPI0619391A2 (pt) * 2005-11-30 2011-10-04 Astrazeneca Ab forma de dosagem farmacêutica oral, processo para a manufatura de uma forma de dosagem de combinação fixa oral, uso de uma forma de dosagem, e, forma de combinação fixa oral farmacêutica
EP2034953A4 (en) * 2006-06-26 2013-05-15 Capricorn Pharma Inc ORAL DISINTEGRATING LAYER COMPOSITIONS
JP2009263305A (ja) * 2008-04-28 2009-11-12 Lion Corp 多層錠剤およびその製造方法
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防/改善・治療薬

Also Published As

Publication number Publication date
KR20130124344A (ko) 2013-11-13
CL2013001566A1 (es) 2014-05-02
CA2819460C (en) 2017-08-01
CN103338774A (zh) 2013-10-02
EA201390814A1 (ru) 2013-11-29
BR112013013571A2 (pt) 2016-10-11
US20130243859A1 (en) 2013-09-19
EP2647381A1 (en) 2013-10-09
CA2819460A1 (en) 2012-06-07
EP2647381A4 (en) 2015-12-23
JP6037840B2 (ja) 2016-12-07
ZA201304366B (en) 2014-02-26
DOP2013000122A (es) 2013-12-15
PE20140005A1 (es) 2014-01-23
JPWO2012074110A1 (ja) 2014-05-19
PH12013501119B1 (en) 2018-04-20
KR101908748B1 (ko) 2018-10-16
PH12013501119A1 (en) 2013-07-22
MY180677A (en) 2020-12-05
TN2013000229A1 (en) 2014-11-10
MX2013006247A (es) 2014-01-31
ECSP13012717A (es) 2013-12-31
WO2012074110A1 (ja) 2012-06-07
CO6721054A2 (es) 2013-07-31
AU2011337549A1 (en) 2013-07-04
SG190717A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CR20130287A (es) Tableta oralmente desintegradora
MY186477A (en) Dry coated tablet
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
PH12016500121B1 (en) Pharmaceutical tablet comprising acetylsalicyclic acid and clopidogrel
BR112014006842A2 (pt) construção de lista de imagens de referência para codificação de vídeo
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
UY31741A (es) Capsula para la prevencion de enfermedades cardiovasculares
CR20160192A (es) Formulación de farmaco de liberación retardada
PH12018500236B1 (en) Tablet
IN2015DN04161A (es)
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2011054930A3 (en) Pharmaceutical solid dosage form
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
WO2010081722A3 (en) Orally disintegrating tablets for the treatment of pain
BR112014019526B8 (pt) Forma de dosagem de liberação rápida e seu método de produção
CL2013000089A1 (es) Tableta de desintegracion rapida en la cavidad oral que contiene particulas nucleares con acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxilico y que estan recubiertas con dos capas.
EA201270269A1 (ru) Фармацевтическая таблетка, содержащая розувастатин кальция
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
UA59388U (ru) Комбинированный лекарственный препарат анальгетического, противовоспалительного и жаропонижающего действия
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
TH153153A (th) ยาเม็ดเคลือบแห้ง
TH134258A (th) ยาเม็ดชนิดแตกตัวในปาก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)